ALBO

Odevixibat (A4250)

Biliary atresia

Stage (next event)

Expected Date

Phase 3 To be Initiated

Q4 2020

Catalyst Info & Data Links

TITLE: Odevixibat for Biliary atresia Phase 3 To be initiated

  • Clinical Trial (NCT04336722): Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 To be initiated 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Q4 2020


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION 

  • With normal function, approximately 95 percent of bile acids released from the liver into the bile ducts to aid in liver function are recirculated to the liver via the IBAT in a process called enterohepatic circulation. In people with cholestatic liver diseases, the bile flow is interrupted, resulting in elevated levels of toxic bile acids accumulating in the liver and serum. Accordingly, a product capable of inhibiting the IBAT could lead to a reduction in bile acids returning to the liver and may represent a promising approach for treating cholestatic liver diseases.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon